Table 2 Characteristics and individual outcomes of patients with metastatic disease treated with bevacizumab-containing therapy

From: Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy

    

Treatment

Outcome

    

Sex

Age (years)

ECOG

Metas. (sites)

Regimen

Line

Initial response

Time to progress (months)

Time to death (months)

Ang-2 (ng ml−1)

VEGF (ng ml−1)

MVD (per HPF)

PC (%)

M

63

1

1

FOLFIRI+BV

1st

Yes

—

—

0.7

0.05

NA

NA

M

67

0

1

XELIRI+BV

1st

Yes

—

—

2.4

0.19

NA

NA

M

57

1

1

FOLFIRI+BV

2nd

Yes

—

—

2.4

0.20

29

80

M

69

1

2

FOLFIRI+BV

1st

Yes

—

—

2.9

0.25

58

56

F

69

1

1

FOLFOX+BV

1st

Yes

—

—

2.9

0.46

42

20

M

56

1

1

FOLFIRI+BV

2nd

Yes

—

—

4.1

0.31

NA

NA

M

59

1

1

XELOX+BV

1st

No

—

—

3.8

0.20

NA

NA

M

70

0

1

XELIRI+BV

1st

Yes

20

—

3.3

0.02

NA

NA

F

54

1

1

FOLFIRI+BV

2nd

Yes

17

—

2.1

0.10

53

60

F

57

1

2

FOLFIRI+BV

1st

Yes

17

—

4.4

0.08

28

28

M

69

1

1

FOLFIRI+BV

1st

Yes

14

—

2.3

0.62

49

24

M

70

1

1

FOLFIRI+BV

2nd

Yes

13

—

1.8

0.20

NA

NA

M

58

0

3

XELOX+BV

1st

Yes

13

—

2.7

0.00a

NA

NA

M

73

1

1

FOLFIRI+BV

1st

Yes

13

—

2.8

0.13

65

36

F

70

1

1

FOLFIRI+BV

1st

Yes

13

—

3.2

0.64

NA

NA

F

45

0

1

XELIRI+BV

1st

Yes

13

—

5.2

0.00a

NA

NA

M

54

1

1

FOLFIRI+BV

1st

Yes

12

—

1.9

0.25

NA

NA

F

75

1

1

XELIRI+BV

1st

Yes

11

—

5.9

0.07

50

72

F

57

1

1

XELIRI+BV

1st

Yes

10

—

3.4

0.00a

NA

NA

F

60

1

1

FOLFIRI+BV

2nd

No

14

—

2.0

0.25

25

64

F

72

1

1

FOLFIRI+BV

2nd

No

10

—

2.9

0.33

NA

NA

F

75

0

1

XELOX+BV

1st

No

10

—

6.3

0.16

NA

NA

F

77

1

3

XELOX+BV

1st

No

8

—

6.5

0.10

47

40

M

71

1

1

XELOX+BV

1st

No

8

—

10.8

0.03

29

72

M

72

0

1

XELIRI+BV

1st

No

10

14

4.5

0.02

26

13

F

52

2

1

XELIRI+BV

1st

No

10

11

11.1

0.02

36

52

M

83

1

1

XEL+BV

1st

No

8

10

3.7

0.10

31

64

M

60

1

1

FOLFOX+BV

2nd

No

7

7

2.4

0.15

NA

NA

F

70

2

1

FOLFOX+BV

2nd

Yes

7

9

7.6

0.39

93

44

F

72

1

1

FOLFOX+BV

1st

No

6

6

3.5

0.08

30

52

M

57

0

2

XELIRI+BV

1st

No

6

16

6.1

0.36

NA

NA

M

77

0

3

XELIRI+BV

1st

No

5

6

12.1

0.19

45

56

M

51

0

2

XELOX+BV

1st

No

4

19

4.4

0.02

NA

NA

F

80

2

2

5-FU/FO+BV

2nd

No

4

4

7.7

0.39

NA

NA

  1. Abbreviations: 5FU/FO=5-fluorouracil/folinic acid; Ang-2=angiopoietin-2 (serum concentration); BV=bevacizumab; ECOG=Eastern Cooperative Oncology Group; F=female; FOLFIRI=5-fluorouracil/folinic acid/irinotecan; FOLFOX=5-fluorouracil/folinic acid/oxaliplatin; HPF=high power field; M=male; Metas.=metastasis (number of organs with metastases); MVD=microvessel density; NA=not analyzed; PC=pericyte coverage; VEGF=vascular endothelial growth factor (serum concentration); XEL=capecitabine; XELIRI=capecitabine/irinotecan; XELOX=capecitabine/oxaliplatin.
  2. aConcentration not measurable.
  3. —, No disease progression or death.
Back to article page